Commercial OpportunityThe VLA15 Lyme vaccine addresses a substantial unmet need and commercial opportunity as there are no approved vaccines for Lyme disease.
Financial OutlookOngoing revenue from commercial vaccines and a high-value partner-funded asset nearing a key data readout contribute to the positive outlook for VALN shares.
Vaccine DevelopmentValneva's co-development of VLA15, a Phase 3 Lyme disease vaccine, offers a de-risked path to potential blockbuster sales.